Karin Schölin Bywall
Karin Schölin Bywall
MSc Public Health
PhD Student
Karin Schölin Bywall is a PhD student in the IMI-funded PREFER project. The project is aiming to investigate methodologies to elicit informed patient preferences regarding the benefits and risks of drugs, from development through the entire cycle, to inform the decision-making process by regulators and HTA bodies.
Karin Schölin Bywall has a master of science in public health from Mälardalen University where she also teached in public health.
E-mail: karin.bywall@crb.uu.se
Phone: +46 18 471 62 49
Risk information
We are investigating risk information from serval perspectives.
Patient preferences
Giving patients a voice in drug development
PREFER is a five year public-private research project where academic researchers and the pharmaceutical industry work together to find out when and where patients want, can and should be involved in drug development
Patient prefrences
Rheumatoid Arthritis
Karin Schölin Bywall will look at how rheumatoid arthritis patient preferences can provide added value in regulatory decision making in the drug development process.
Methodology, rheumatoid arthritis and patient involvement
Drugs should benefit patients. By extension, they should have a say in designing research meant to find out what they think about drugs. Here, Karin Schölin Bywall shares her thoughts about involving patients in research and working together with stakeholders.
